#DEST – Destiny Pharma
Shares in issue – 59.8m
MCAP – £58m at close 11/1/21
TRADE ONLY

XF73 is Destinys lead asset. Its potential use is prevention of post surgery staphylococcus aureus (MRSA – methicillin resistant staphylococcus aureus).
#DEST -
Sales pipeline – est. commercial opportunity US alone is $1bn
Free Float – BoD hold over 13% of the co & an additional 50% is held by investors over the 3% threshold. Leaving total free float at about 37%.
Funded Status – Fully funded through to 2022
#DEST - due to the nature of the sector this is high risk / high reward. I am in for a trade into the run up to data read out for Q1 '21. Given data so far, Bactroban no longer available & the massive opportunity in comparison to MCAP it could go much higher in anticipation.
#DEST - 1/3 of people carry MRSA & carriers are 10X more likely to have post surgical infections. Infections & complications cost <$10bn & put 40m people at risk. Image shows QIDP status provides10yr exclusivity in the US. Recruitment is now complete since slide was released.
#DEST - Mupirocin (Bactroban - GSK) was the only drug used to prevent MRSA although never approved for this. Bactroban was discontinued in the US. Creating a medical need for a post surgical preventative (no competition). Most seemed to account for a market share with Bactroban.
#DEST - Mupirocin (Bactroban - GSK) was the only drug used to prevent MRSA although never approved for this. Bactroban was discontinued in the US. Creating a medical need for a post surgical preventative (no competition). Most seemed to account for a market share with Bactroban.
#DEST - Mupirocin (Bactroban - GSK) was the only drug used to prevent MRSA although never approved for this. Bactroban was discontinued in the US. Creating a medical need for a post surgical preventative (no competition). Most seemed to account for a market share with Bactroban.
#DEST -

Interesting interview released late last year with the CEO of DEST. https://www.equitydevelopment.co.uk/research/differentiated-anti-infectives-0-1-0-0-0-0
Interview with CEO, Neil Clark

The M3 transaction transforms Destiny Pharma and catapults its pipeline into late stage development.

https://www.equitydevelopment.co.uk/research/differentiated-anti-infectives-0-1-0-0-0-0
You can follow @SLowie100.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.